Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia - PubMed (original) (raw)
Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia
Marta Pevida et al. Brain Res Bull. 2013 Jun.
Abstract
The antineoplastic paclitaxel induces a sensory neuropathy that involves the spinal release of neuroinflammatory mediators and activation of glial cells. Although the chemokine CCL2 can evoke glial activation and its participation in neuropathic pain has been demonstrated in other models, its involvement in paclitaxel-evoked neuropathy has not been previously explored. Paclitaxel-evoked cold hypernociception was assessed in mice by the unilateral cold plate test and the effects on cold hyperalgesia of the CCR2 antagonist RS 504393, the CCR1 antagonist J113863, the microglial inhibitor minocycline or an anti-CCL2 antibody were tested. Furthermore, ELISA measurements of CCL2 concentration and immunohistochemical assays of Iba-1 and GFAP, markers of microglial and astroglial cells respectively, were performed in the lumbar spinal cord. Cold hypernociception measured 3 days after the administration of paclitaxel (10mg/kg) was inhibited by the s.c. (0.3-3mg/kg) or i.t. (1-10 μg) administration of RS 504393 but not of J113863 (3-30 mg/kg). CCL2 levels measured by ELISA in the lumbar spinal cord were augmented in mice treated with paclitaxel and the i.t. administration of an anti-CCL2 antibody completely suppressed paclitaxel-evoked cold hyperalgesia, strongly suggesting that CCL2 is involved in the hypernociception evoked by this taxane. Besides, the implication of microglial activation is supported by the increase in the immunolabelling of Iba-1, but not GFAP, in the spinal cord of paclitaxel-treated mice and by the inhibition of cold hyperalgesia produced by the i.t. administration of the microglial inhibitor minocycline (1-10 nmol). Finally, the neutralization of spinal CCL2 by the i.t. administration of a selective antibody for 3 days almost totally inhibited paclitaxel-evoked microglial activation. In conclusion, our results indicate that paclitaxel-evoked cold hypernociception depends on the activation of CCR2 due to the spinal release of CCL2 and the subsequent microglial activation.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
- Involvement of spinal chemokine CCL2 in the hyperalgesia evoked by bone cancer in mice: a role for astroglia and microglia.
Pevida M, González-Rodríguez S, Lastra A, García-Suárez O, Hidalgo A, Menéndez L, Baamonde A. Pevida M, et al. Cell Mol Neurobiol. 2014 Jan;34(1):143-56. doi: 10.1007/s10571-013-9995-7. Cell Mol Neurobiol. 2014. PMID: 24122510 - Involvement of glutamate NMDA and AMPA receptors, glial cells and IL-1β in the spinal hyperalgesia evoked by the chemokine CCL2 in mice.
Baamonde A, Hidalgo A, Menéndez L. Baamonde A, et al. Neurosci Lett. 2011 Sep 20;502(3):178-81. doi: 10.1016/j.neulet.2011.07.038. Epub 2011 Jul 30. Neurosci Lett. 2011. PMID: 21827829 - Chemokines CCL2 and CCL7, but not CCL12, play a significant role in the development of pain-related behavior and opioid-induced analgesia.
Kwiatkowski K, Popiolek-Barczyk K, Piotrowska A, Rojewska E, Ciapała K, Makuch W, Mika J. Kwiatkowski K, et al. Cytokine. 2019 Jul;119:202-213. doi: 10.1016/j.cyto.2019.03.007. Epub 2019 Apr 16. Cytokine. 2019. PMID: 31003094 - Goshajinkigan attenuates paclitaxel-induced neuropathic pain via cortical astrocytes.
Takanashi K, Shibata K, Mizuno K, Komatsu R, Koizumi S. Takanashi K, et al. Pharmacol Res Perspect. 2021 Dec;9(6):e00850. doi: 10.1002/prp2.850. Pharmacol Res Perspect. 2021. PMID: 34676996 Free PMC article. Review. - Peripheral benzodiazepine receptors: are they potential biomarkers for glial activation in pain states?
Romero-Sandoval EA. Romero-Sandoval EA. Eur J Pain. 2013 May;17(5):635-7. doi: 10.1002/j.1532-2149.2012.00283.x. Eur J Pain. 2013. PMID: 23526770 Review. No abstract available.
Cited by
- Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain.
Navia-Pelaez JM, Choi SH, Dos Santos Aggum Capettini L, Xia Y, Gonen A, Agatisa-Boyle C, Delay L, Gonçalves Dos Santos G, Catroli GF, Kim J, Lu JW, Saylor B, Winkels H, Durant CP, Ghosheh Y, Beaton G, Ley K, Kufareva I, Corr M, Yaksh TL, Miller YI. Navia-Pelaez JM, et al. J Exp Med. 2021 Jul 5;218(7):e20202059. doi: 10.1084/jem.20202059. Epub 2021 May 10. J Exp Med. 2021. PMID: 33970188 Free PMC article. - Transplant-mediated enhancement of spinal cord GABAergic inhibition reverses paclitaxel-induced mechanical and heat hypersensitivity.
Bráz JM, Wang X, Guan Z, Rubenstein JL, Basbaum AI. Bráz JM, et al. Pain. 2015 Jun;156(6):1084-1091. doi: 10.1097/j.pain.0000000000000152. Pain. 2015. PMID: 25760475 Free PMC article. - Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.
Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S. Staff NP, et al. Exp Neurol. 2020 Feb;324:113121. doi: 10.1016/j.expneurol.2019.113121. Epub 2019 Nov 21. Exp Neurol. 2020. PMID: 31758983 Free PMC article. Review. - Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain.
Pawlik K, Mika J. Pawlik K, et al. Molecules. 2023 Jul 30;28(15):5766. doi: 10.3390/molecules28155766. Molecules. 2023. PMID: 37570736 Free PMC article. Review. - Pathomechanisms of Paclitaxel-Induced Peripheral Neuropathy.
Klein I, Lehmann HC. Klein I, et al. Toxics. 2021 Sep 22;9(10):229. doi: 10.3390/toxics9100229. Toxics. 2021. PMID: 34678925 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous